论文部分内容阅读
目的探讨蚓激酶对缺血性脑血管病恢复期合并高脂血症患者血脂及血液流变学的影响。方法 58例缺血性脑血管病恢复期合并高脂血症患者,随机分为治疗组(B组)和对照组(A组)各29例,均予瑞舒伐他汀降脂治疗10mg,qd,B组在此基础上加用蚓激酶60万U,tid。治疗12周后,比较两组治疗前后的差异。结果 B组治疗12周后,全血粘度、血浆粘度、红细胞聚集指数、血浆纤维蛋白原含量及甘油三酯下降均较A组更显著(P<0.01)。结论蚓激酶对缺血性脑血管病患者血脂及血液流变学指标均有不同程度的改善,可应用于缺血性脑血管病的二级预防。
Objective To investigate the effects of lumbrokinase on serum lipids and hemorheology in patients with congestive heart failure and convalescence of ischemic cerebrovascular disease. Methods 58 patients with concomitant hyperlipemia and recovery from ischemic cerebrovascular disease were randomly divided into treatment group (group B) and control group (group A), with 29 cases in each group. All patients were given rosuvastatin and lipid lowering therapy for 10 mg qd B group on the basis of plus Lumbrokinase 600,000 U, tid. After 12 weeks of treatment, the differences between the two groups before and after treatment were compared. Results After 12 weeks of treatment, whole blood viscosity, plasma viscosity, erythrocyte aggregation index, plasma fibrinogen content and triglyceride decreased more significantly in group B than those in group A (P <0.01). Conclusion Lumbrokinase can improve the level of blood lipid and hemorheology in patients with ischemic cerebrovascular disease. It can be used in secondary prevention of ischemic cerebrovascular disease.